- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04670276
Conservative Treatment of Gastrointestinal Fistulas by Endoscopic Injection of tSVFem (tSVFem)
Conservative Treatment of Gastrointestinal Fistulas by Endoscopic Injection of Emulsified Adipose Tissue Stromal Vascular Fraction (tSVFem)
Gastrointestinal (GI) fistula is a complex condition with high mortality and requiring a multidisciplinary management.
The aim of this study is to exploit the regenerative-tissue capacities of autologous emulsified adipose tissue-derived stromal vascular fraction (tSVFem, widely used in other medical fields - like plastic surgery -for different purposes) harvested and delivered locally by endoscopy to close the GI fistula.
The proposed technique for the treatment of GI fistulas with tSVFem requires a minimal, inexpensive, easily reproducible mechanical manipulation of autologous adipose tissue without necessity of any enzymatic digestion or cell expansion.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Gastrointestinal fistula may be a life-threatening condition caused by several types of injuries (iatrogenic, traumatic, post-operative), requiring complex and multidisciplinary management. To date, no clear guidelines have been drawn up for the treatment, that may include a conservative, minimally invasive, or major surgical approach depending on the patient's specific clinical characteristics. Furthermore, patients with fistulas are often fragile, and surgical treatments are highly risky and invasive. Less invasive treatments such as stenting, endoluminal endoscopic vacuum therapy and suturing are widely employed, but these treatments often require long hospitalization, highly skilled operators, without certain results and with high rates of complications.
The aim of this study is to exploit the regenerative-tissue capacities of autologous emulsified adipose tissue-derived stromal vascular fraction (tSVFem, widely used in other medical fields - like plastic surgery -for different purposes) harvested and delivered locally by endoscopy to close the GI fistula. Indeed, the anti-inflammatory and regenerative-tissue promoting effects of tSVFem may safely promote rapid and effective tissue healing as alternative, and in this setting they were not investigated before. Fistulas are often long-standing chronic conditions, thus healing mechanisms are delayed and subverted in favor of inflammation and fibrosis, resembling chronic inflammatory diseases. Delivery of tSVFem is a promising new approach that promotes healing in virtue of its immunosuppressive, immunomodulatory, pro-angiogenic and regenerative potentials. Since the grafted material used in this study is autologous, there is no risk for rejection. All the procedures are performed under general anesthesia with orotracheal intubation or laryngeal mask. Approximately 30 cc of fat are harvested from the superficial layer of subcutaneous tissue by a 2.1 mm microcannula with 4, 1-mm size holes, arranged in a single raw, to get the so-called "microfat". Twenty cc of the harvested microfat are mechanical emulsified by sequential passages through 2.4mm and 1.2mm filters, and a 600/400 μm disposable filtering device.
Then the material is centrifuged at 3000 rounds for three minutes, obtaining the tSVFem after removal of supernatant fraction and oil released upon mature adipocytes mechanical disruption.
Subsequently, an endoscopy is performed to inject 10 cc of microfat into the fistula (through a 6-French catheter) until it was completely filled. Then, with a 22 Gauge endoscopic needle, a total of 1-2 cc of tSVFem were injected into the submucosa of the 4 quadrants of the fistula borders, to obliterate it completely.
A radiologic and endoscopic control at day-7 is done to evaluate complete healing of the fistula.
The technique proposed by the investigators for the treatment of GI fistulas with tSVFem requires a minimal, inexpensive, easily reproducible mechanical manipulation of autologous adipose tissue without necessity of any enzymatic digestion or cell expansion.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Dania Nachira
- Phone Number: 00390630155692
Study Locations
-
-
-
Roma, Italy, 00168
- Recruiting
- Fondazione Policlinico Agostino Gemelli IRCCS
-
Contact:
- Venanzio Porziella
- Phone Number: 00390630156353
- Email: Venanzio.porziella@policlinicogemelli.it
-
Principal Investigator:
- Venanzio Porziella, MD
-
Sub-Investigator:
- Dania Nachira, MD
-
Principal Investigator:
- Angelo Trivisonno, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
• Patients affected by GI fistulas, not fit for surgical treatments of after failure of conventional conservative treatments
Exclusion Criteria:
- Enteroenteric fistulas
- Patients who do not sign informed consent form
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Experimental arm
Patients treated by endoscopic injection of emulsified adipose tissue stromal vascular fraction
|
Endoscopic injection of 10 cc of autologous microfat into the fistula (through a 6-French catheter), until it was completely filled, and a total of 1-2 cc of tSVFem (through a 22G endoscopic needle) into the submucosa of the 4 quadrants of the fistula borders, to obliterate it completely.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fistula healing
Time Frame: 7 days after the injection procedure of tSVFem
|
Rate of healing of fistula at endoscopy and gastrografin swallow
|
7 days after the injection procedure of tSVFem
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment adverse events and complications
Time Frame: During the procedure, 7 days after and at 1-2 month follow-up
|
To evaluate the percentage of patients that developed adverse events or any complications during and after the treatment proposed
|
During the procedure, 7 days after and at 1-2 month follow-up
|
Collaborators and Investigators
Investigators
- Principal Investigator: Venanzio Porziella, MD, Fondazione Policlinico Universitario A. Gemelli, IRCCS
Publications and helpful links
General Publications
- Panes J, Garcia-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, Ferrante M, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. Lancet. 2016 Sep 24;388(10051):1281-90. doi: 10.1016/S0140-6736(16)31203-X. Epub 2016 Jul 29.
- Brinster CJ, Singhal S, Lee L, Marshall MB, Kaiser LR, Kucharczuk JC. Evolving options in the management of esophageal perforation. Ann Thorac Surg. 2004 Apr;77(4):1475-83. doi: 10.1016/j.athoracsur.2003.08.037.
- Porziella V, Nachira D, Boskoski I, Trivisonno A, Costamagna G, Margaritora S. Emulsified stromal vascular fraction tissue grafting: a new frontier in the treatment of esophageal fistulas. Gastrointest Endosc. 2020 Dec;92(6):1262-1263. doi: 10.1016/j.gie.2020.06.019. Epub 2020 Jul 4. No abstract available.
- Kuehn F, Loske G, Schiffmann L, Gock M, Klar E. Endoscopic vacuum therapy for various defects of the upper gastrointestinal tract. Surg Endosc. 2017 Sep;31(9):3449-3458. doi: 10.1007/s00464-016-5404-x. Epub 2017 Jan 11.
- Brangewitz M, Voigtlander T, Helfritz FA, Lankisch TO, Winkler M, Klempnauer J, Manns MP, Schneider AS, Wedemeyer J. Endoscopic closure of esophageal intrathoracic leaks: stent versus endoscopic vacuum-assisted closure, a retrospective analysis. Endoscopy. 2013 Jun;45(6):433-8. doi: 10.1055/s-0032-1326435. Epub 2013 Jun 3.
- Ceccarelli S, Pontecorvi P, Anastasiadou E, Napoli C, Marchese C. Immunomodulatory Effect of Adipose-Derived Stem Cells: The Cutting Edge of Clinical Application. Front Cell Dev Biol. 2020 Apr 17;8:236. doi: 10.3389/fcell.2020.00236. eCollection 2020.
- Angelo Trivisonno, Marc Abecassis, Massimo Monti et al. Adipose Tissue: From Energy Reservoir to a Source of Cells for Epithelial Tissue Engineering. In: Stem Cells in Aesthetic Procedures: Springer Berlin Heidelberg,2014:303-326
- Trivisonno A, Nachira D, Boskoski I, Calcagni F, Tringali A, Costamagna G, Margaritora S, Porziella V. Autologous Fat Grafting Restores Soft-tissue Contour Deformities after Vascular Anomaly: Widening the Horizons of Employment of Autologous Fat Grafting. Plast Reconstr Surg Glob Open. 2019 Nov 27;7(11):e2518. doi: 10.1097/GOX.0000000000002518. eCollection 2019 Nov. No abstract available.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3127 prot.num 0043082/20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastrointestinal Fistula
-
The Oregon ClinicUnknownGastrointestinal Fistula | Gastrointestinal PerforationUnited States
-
Jinling Hospital, ChinaUnknownLow-output External Gastrointestinal FistulaChina
-
Jinling Hospital, ChinaUnknownLow-output External Gastrointestinal FistulaChina
-
University Hospital, AkershusUniversity Hospital, Linkoeping; Region Örebro County; Uppsala University HospitalCompletedPerianal FistulaNorway
-
Zagazig UniversityCompletedTranssphincteric Anal FistulaEgypt
-
London North West Healthcare NHS TrustCompletedFistula in Ano | Ano FistulaUnited Kingdom
-
Rush University Medical CenterTerminatedRectal Fistula | Anal Fistula | Fistula in Ano | Transsphincteric FistulaUnited States
-
Tehran University of Medical SciencesRecruitingFistula PerianalIran, Islamic Republic of
-
Sykehuset Innlandet HFWithdrawn
-
The University of Texas Health Science Center,...CENTER FOR CLINICAL AND TRANSLATIONAL SCIENCESRecruiting
Clinical Trials on injection of emulsified adipose tissue stromal vascular fraction
-
Hvidovre University HospitalCompletedOsteoarthritis | Stem CellsDenmark
-
Translational BiosciencesWithdrawn
-
Dr. Himanshu Bansal FoundationCompletedNonunion of FractureIndia
-
University of Science Ho Chi Minh CityVan Hanh General Hospital; GeneWorld Co., Ltd., Ho Chi Minh; 115 People's HospitalCompletedAutologous Adipose Stem Cells and Platelet Rich Plasma Therapy for Patients With Knee OsteoarthritisKnee OsteoarthritisVietnam
-
University of FloridaCompleted
-
Kasiak Research Pvt. Ltd.UnknownCritical Limb IschemiaIndia
-
Samuel VilchezNational Autonomous University of Nicaragua; Ministerio de Salud de Nicaragua; GID BIOCompletedChronic Renal Failure of Unknown CauseNicaragua
-
Shanghai Jiao Tong University School of MedicineUnknown
-
Shanghai Jiao Tong University School of MedicineWest China Hospital; Guangzhou General Hospital of Guangzhou Military Command; Second Affiliated Hospital of Suzhou University and other collaboratorsUnknownSkin; Deformity, Due to ScarChina
-
Wake Forest University Health SciencesNot yet recruitingOsteoarthritisUnited States